| HOME >> BIOLOGY >> TECHNOLOGY |
BERKELEY HEIGHTS, N.J., Oct. 8 /PRNewswire/ -- Clinsys Clinical Research, Inc., a therapeutically focused clinical research organization, today announced the relocation of its corporate headquarters to accommodate the company's significant growth and plans for future expansion. The new, larger facility is located in Bedminster, New Jersey.
"Our new headquarters, combined with our recent expansion of operations in Raleigh, North Carolina and Dusseldorf, Germany, offers many advantages to Clinsys and our sponsors," said David E. Williams, Chief Executive Officer of Clinsys Clinical Research. Mr. Williams continues, "The relocation strategically keeps Clinsys in the center of one of the largest biopharmaceutical clusters and experienced employee pools in the country. Our new headquarters will afford us enhanced operational performance from which to continue to provide exceptional service to our existing and new sponsors."
Clinsys will occupy the new facility on Monday, October 15. The new address is:
One Crossroads Drive, Building A, Second Floor, Bedminster, New Jersey 07921.
The new corporate telephone number is +1 908 947 7777.
The new corporate fax number is +1 908 947 7953.
About Clinsys Clinical Research, Inc.
Clinsys Clinical Research, Inc.(R), is a therapeutically focused
clinical research organization and a Jubilant Organosys company,
headquartered in Bedminster, New Jersey. Clinsys has operations in Raleigh,
North Carolina; Philadelphia, Pennsylvania; Dusseldorf, Germany; Gent,
Belgium; Noida and Bangalore, India. Clinsys provides pharmaceutical and
biotechnology companies a broad range of clinical research services in
support of Phase I -- IV drug development: project management, medical and
clinical monitoring, investigator and patient recruitment, site management,
biostatistics, data management, drug safety, quality assurance, regulatory
affairs and medical writing services. Clinsys has expertise in a wide r
'/>"/>
| SOURCE Clinsys Clinical Research, Inc. Copyright©2007 PR Newswire. All rights reserved |